I
Ingrid U. Scott
Researcher at Pennsylvania State University
Publications - 549
Citations - 24172
Ingrid U. Scott is an academic researcher from Pennsylvania State University. The author has contributed to research in topics: Visual acuity & Endophthalmitis. The author has an hindex of 79, co-authored 524 publications receiving 22220 citations. Previous affiliations of Ingrid U. Scott include Aberdeen Royal Infirmary & Penn State Milton S. Hershey Medical Center.
Papers
More filters
Journal ArticleDOI
Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema
Michael J. Elman,Lloyd Paul Aiello,Roy W. Beck,Neil M. Bressler,Susan B. Bressler,Allison R. Edwards,Frederick L. Ferris,Scott M. Friedman,Adam R. Glassman,Kellee M. Miller,Ingrid U. Scott,Cynthia R. Stockdale,Jennifer K. Sun +12 more
TL;DR: Intravitreal ranibizumab with prompt or deferred laser is more effective through at least 1 year compared with prompt laser alone for the treatment of DME involving the central macula.
Journal ArticleDOI
A Randomized Trial Comparing the Efficacy and Safety of Intravitreal Triamcinolone With Observation to Treat Vision Loss Associated With Macular Edema Secondary to Central Retinal Vein Occlusion: The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study Report 5
Michael S. Ip,Ingrid U. Scott,Paul C. VanVeldhuisen,Neal Oden,Barbara A Blodi,Marian R. Fisher,Lawrence J. Singerman,Michael J. Tolentino,Clement K. Chan,Victor H. Gonzalez +9 more
TL;DR: Intravitreal triamcinolone is superior to observation for treating vision loss associated with macular edema secondary to CRVO in patients who have characteristics similar to those in the SCORE-CRVO trial.
Journal ArticleDOI
Expanded 2-Year Follow-up of Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema
Michael J. Elman,Neil M. Bressler,Haijing Qin,Roy W. Beck,Frederick L. Ferris,Scott M. Friedman,Adam R. Glassman,Ingrid U. Scott,Cynthia R. Stockdale,Jennifer K. Sun +9 more
TL;DR: The expanded 2-year results reported are similar to results published previously and reinforce the conclusions originally reported: Ranibizumab should be considered for patients with DME and characteristics similar to those of the cohort in this clinical trial, including vision impairment with D ME involving the center of the macula.
Journal ArticleDOI
A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema.
Ingrid U. Scott,Allison R. Edwards,Roy W. Beck,Neil M. Bressler,Clement K. Chan,Michael J. Elman,Scott M. Friedman,Craig M. Greven,Raj K. Maturi,Dante J. Pieramici,Michel Shami,Lawrence J. Singerman,Cynthia R. Stockdale +12 more
TL;DR: It is demonstrated that intravitreal bevacizumab can reduce DME in some eyes, but the study was not designed to determine whether treatment is beneficial, and a phase III trial would be needed for that purpose.
Journal ArticleDOI
Acute endophthalmitis following intravitreal triamcinolone acetonide injection
Darius M. Moshfeghi,Peter K. Kaiser,Ingrid U. Scott,Jonathan E. Sears,Matthew S. Benz,Juan P. Sinesterra,Richard S. Kaiser,Sophie J. Bakri,Raj K. Maturi,Jonathan B. Belmont,Paul M. Beer,Timothy G. Murray,Hugo Quiroz-Mercado,William F. Mieler +13 more
TL;DR: In this paper, the authors report the clinical features, causative organisms, management, and visual acuity outcomes of eight eyes of eight patients who developed acute postoperative endophthalmitis following intravitreal injection of triamcinolone acetonide (IVTA).